H. Mouridsen

H. Mouridsen, M. Melbye, N. Kroman, 2002, Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society.

Adjuvant systemic therapy in breast cancer; a review.

H. Mouridsen, T. Palshof, 1983, European journal of cancer & clinical oncology.

BRCA1 andBRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age

J. Olsen, Å. Borg, J. Bergthórsson, 2001, Journal of medical genetics.

Selection of large and objectively measurable target lesions in EORTC phase II trials: impact on recruitment and response rate. EORTC Soft Tissue and Bone Sarcoma Group (STBSG).

M. van Glabbeke, J. Verweij, H. Mouridsen, 1993, European journal of cancer.

Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma Group.

J. Verweij, H. Mouridsen, A. V. van Oosterom, 1992, Seminars in oncology.

Lack of effect of gold therapy on abnormal IgG and IgM metabolism in rheumatoid arthritis.

H. Mouridsen, N. Rossing, O. Baerentsen, 1974, Arthritis and rheumatism.

Immunoglobulin (IgG and IgM) metabolism in patients with rheumatoid arthritis.

H. Mouridsen, N. Rossing, O. Baerentsen, 1973, Scandinavian journal of clinical and laboratory investigation.

New cytotoxic drugs in treatment of breast cancer.

H. Mouridsen, 1990, Acta oncologica.

Endocrine therapy of advanced breast cancer.

H. Mouridsen, C. Rose, Mouridsen Ht, 1988, Acta oncologica.

Advanced breast cancer--new approaches to treatment: workshop report.

R. Paridaens, H. Mouridsen, 1988, European journal of cancer & clinical oncology.

Treatment of advanced breast cancer with tamoxifen.

H. Mouridsen, C. Rose, 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer

J. Bergh, H. Mouridsen, B. Nordenskjöld, 2008, Acta oncologica.

Letrozole in advanced breast cancer: the PO25 trial

H. Mouridsen, 2007, Breast Cancer Research and Treatment.

Oral clodronate in breast cancer patients with bone metastases: a randomized study

M. Groenvold, H. Mouridsen, B. Ejlertsen, 1999, Journal of internal medicine.

Nordic trials of adjuvant therapy in primary breast cancer.

H. Mouridsen, 1998, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Inter- and intraobserver variability in the histopathological diagnosis of medullary carcinoma of the breast, and its prognostic implications

K. Zedeler, H. Mouridsen, T. Schiødt, 1989, Breast Cancer Research and Treatment.

Tamoxifen in advanced breast cancer.

H. Mouridsen, J. Patterson, T. Palshof, 1978, Cancer treatment reviews.

Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer

H. Mouridsen, K. Andersen, H. Brincker, 2005, Breast Cancer Research and Treatment.

How to improve cytotoxic therapy in advanced breast cancer.

L. Bastholt, H. Mouridsen, 1990, Acta oncologica.

How to improve adjuvant treatment results in postmenopausal patients.

H. Mouridsen, 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Oral mucosal lesions, microbial changes, and taste disturbances induced by adjuvant chemotherapy in breast cancer patients.

N. Brünner, H. Mouridsen, S. Jensen, 2008, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

CHEMOTHERAPY AND SURVIVAL IN BREAST CANCER

T. Powles, R. Livingston, H. Mouridsen, 1980, The Lancet.

Clinical and Histopathological Prognostic Factors in Chondrosarcomas

H. Mouridsen, T. Schiødt, B. Lund, 1997, Sarcoma.

A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement

O. S. Nielsen, L. Bastholt, H. Mouridsen, 2004, Cancer Chemotherapy and Pharmacology.

Variations in prognostic factors in primary breast cancer throughout the menstrual cycle.

H. Mouridsen, K. Andersen, N. Kroman, 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer

O. S. Nielsen, L. Bastholt, H. Mouridsen, 2004, Cancer Chemotherapy and Pharmacology.

Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients.

H. Mouridsen, A. V. van Oosterom, I. Smith, 1984, European journal of cancer & clinical oncology.

Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas.

R. Sylvester, A. Santoro, H. Mouridsen, 1987, European journal of cancer & clinical oncology.

Predicting recurrence in patients with breast cancer from cumulative laboratory results: a new technique for the application of time series analysis.

H. Mouridsen, P. Winkel, M. W. Bentzon, 1982, Clinical chemistry.

Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies.

G. Giaccone, H. Mouridsen, H. Eidtmann, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone.

L. Bastholt, H. Mouridsen, P. Dombernowsky, 1986, Breast cancer research and treatment.

Second cancer following cancer of the female breast in Denmark, 1943-80.

H. Mouridsen, M. Ewertz, 1985, National Cancer Institute monograph.

The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients

L. Bastholt, H. Mouridsen, C. Rose, 2004, Cancer Chemotherapy and Pharmacology.

Systemic Therapy of Advanced Breast Cancer

H. Mouridsen, 2012, Drugs.

Endocrine Treatment of Advanced Breast Cancer

H. Mouridsen, 1986 .

[Mammography screening in the county of Copenhagen. Results of the first three screening rounds].

F. Hirsch, H. Mouridsen, I. Vejborg, 2002, Ugeskrift for læger.

Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer.

H. Storm, H. Mouridsen, M. Andersson, 1991, Journal of the National Cancer Institute.

Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma.

H. Mouridsen, M. Melbye, N. Kroman, 2004, Cancer.

Danish Breast Cancer Cooperative Group--DBCG.

H. Mouridsen, K. Fischerman, 1977, Ugeskrift for laeger.

Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Updated safety analysis of trial BIG 1–98

A. Coates, B. Thürlimann, L. Mauriac, 2007 .

Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98

M. Fernö, H. Mouridsen, L. Rydén, 2017, Breast Cancer Research and Treatment.

Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial.

G. Viale, K. Nielsen, B. Rasmussen, 2012 .

Adjuvant tamoxifen in postmenopausal high-risk breast cancer patients: present status of Danish Breast Cancer Cooperative Group trials.

H. Mouridsen, P. Dombernowsky, C. Rose, 1986, NCI monographs : a publication of the National Cancer Institute.

Endocrine management of advanced breast cancer.

H. Mouridsen, C. Rose, 1989, Hormone research.

CMF versus CMF plus tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial.

R. Sylvester, H. Mouridsen, T. Palshof, 1980, European journal of cancer.

Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma.

J. Verweij, A. Santoro, H. Mouridsen, 1993, Cancer chemotherapy and pharmacology.

Improved progression-free survival from the addition of vinorelbine to epirubicin in first line chemotherapy of metastatic breast cancer

H. Mouridsen, J. Andersen, B. Ejlertsen, 2001 .

Phase II trial of prednimustine, L‐1031, (NSC‐134087) in advanced breast cancer

H. Mouridsen, P. Dombernowsky, H. Mouridsen, 1980, Cancer.

Aromatase inhibitors in advanced breast cancer.

H. Mouridsen, 2004, Seminars in oncology.

Doxorubicin in relapsed soft tissue sarcoma: justification of phase II evaluation of new drugs in this disease. An EORTC Soft Tissue and Bone Sarcoma Group Study.

R. Sylvester, H. Mouridsen, A. V. van Oosterom, 1990, European journal of cancer.

Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.

J. Forbes, R. Gelber, R. Paridaens, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic significance of residual cancer tissue after diagnostic biopsy in breast carcinoma. Three-year short-term results.

H. Mouridsen, J. Kjaergaard, K. Andersen, 1984, European journal of cancer & clinical oncology.

Organisation of the Danish adjuvant trials in breast cancer.

M. Ro̸rth, H. Mouridsen, H. Johansen, 1981, Danish medical bulletin.

Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF Combination with epirubicin

J. Bergh, H. Mouridsen, M. Andersson, 1999 .

Weekly oral idarubicin in postmenopausal women with advanced breast cancer. A phase II study.

L. Bastholt, H. Mouridsen, A. Jakobsen, 1990, Acta oncologica.

Oral idarubicin in the treatment of advanced breast cancer.

L. Bastholt, H. Mouridsen, A. Jakobsen, 1989, Acta oncologica.

Vinorelbine as first-line or second-line therapy for advanced breast cancer: A Phase I-II trial by the Danish Breast Cancer Co-operative Group

H. Mouridsen, B. Ejlertsen, J. Andersen, 2008, Acta oncologica.

Endocrine Aspects in Adjuvant Therapy for Early Breast Cancer

R. Gelber, A. Goldhirsch, H. Mouridsen, 1986 .

Plasma and Serum Levels of Tissue Inhibitor of Metalloproteinases-1 Are Associated with Prognosis in Node-negative Breast Cancer

N. Brünner, H. Mouridsen, S. Møller, 2008, Molecular & Cellular Proteomics.

Primary Tumor Levels of Tissue Inhibitor of Metalloproteinases-1 Are Predictive of Resistance to Chemotherapy in Patients with Metastatic Breast Cancer

N. Brünner, J. Foekens, M. Look, 2006, Clinical Cancer Research.

PrimaryTumor Levels ofTissue Inhibitor of Metalloproteinases-1 Are Predictive of Resistance to Chemotherapy in Patients with Metastatic Breast Cancer

J. Foekens, M. Look, M. M. Gelder, 2006 .

Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients.

H. Mouridsen, C. Rose, K. Andersen, 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Letrozole versus Tamoxifen as First-Line Treatment for Metastatic Breast Cancer

H. Mouridsen, 2003 .

A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy.

C. Desmedt, D. Larsimont, M. Buyse, 2009 .

Anthracyclines in the Treatment of Early Breast Cancer

H. Mouridsen, Dr H. T. Mouridsen, 2012, Drugs.

Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study.

M. van Glabbeke, J. Verweij, M. Glabbeke, 1993, European journal of cancer.

The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise

H. Mouridsen, M. Jensen, S. Møller, 2008, Acta oncologica.

Quality control of end results in a Danish adjuvant breast cancer multi-center study.

H. Mouridsen, K. Andersen, P. S. Hansen, 1997, Acta oncologica.

Exemestane following tamoxifen in postmenopausal women with primary breast cancer.

H. Mouridsen, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant endocrine therapy of primary operable breast cancer. Report on the Copenhagen breast cancer trials.

H. Mouridsen, T. Palshof, J. Daehnfeldt, 1980, European journal of cancer.

Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Critical review of adjuvant therapy in premenopausal patients.

H. Mouridsen, 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Adjuvant Chemotherapy in Premenopausal Patients: A More Complicated Form of Oophorectomy?

R. Gelber, A. Goldhirsch, H. Mouridsen, 1987 .

Impact of axillary dissection on staging and regional control in breast tumors < or = 10 mm--the DBCG experience. The Danish Breast Cancer Cooperative Group (DBCG), Rigshisoutalet, Copenhagen, Denmark.

H. Mouridsen, C. Axelsson, M. Jensen, 2000, Acta oncologica.

Evaluation of single-drug versus multiple-drug chemotherapy in the treatment of advanced breast cancer.

H. Mouridsen, T. Palshof, M. Brahm, 1977, Cancer treatment reports.

Incidence and methodologic aspects of the occurrence of liver metastases in recurrent breast cancer

H. Mouridsen, I. Vejborg, S. Daugaard, 1987, Cancer.

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

J. Forbes, R. Gelber, R. Paridaens, 2005, The New England journal of medicine.

Therapeutic effect of tamoxifen alone versus tamoxifen in combination wtih gestagen and oestrogen in advanced breast cancer.

H. Mouridsen, C. Rose, T. Palshof, 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

A phase III trial comparing prednimustine (LEO 1031) to chlorambucil plus prednisolone in advanced breast cancer

M. Ro̸rth, H. Mouridsen, P. Dombernowsky, 1983, Cancer.

Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women.

H. Mouridsen, C. Rose, T. Palshof, 1979, Cancer treatment reports.

Treatment of Advanced Breast Cancer with Progestins: A review

H. Mouridsen, C. Rose, M. Salimtschik, 1981, Acta obstetricia et gynecologica Scandinavica. Supplement.

Principles and indications of endocrine treatment of advanced breast cancer.

H. Mouridsen, T. Palshof, 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Prednisolone in the treatment of severe malignant hypercalcaemia in metastatic breast cancer: a randomized study

H. Mouridsen, B. Ejlertsen, I. Transbøl, 1992, Journal of Internal Medicine.

Malignant haemangiopericytomas and haemangioendotheliosarcomas: an immunohistochemical study

H. Mouridsen, H. Johansen, K. Hou‐Jensen, 1988, Histopathology.

Clinical features of malignant haemangiopericytomas and haemangioendotheliosarcomas.

H. Mouridsen, K. Hou‐Jensen, S. Daugaard, 1988, Acta oncologica.

Integrating Proteomic and Functional Genomic Technologies in Discovery-driven Translational Breast Cancer Research*

Lars Bolund, Jiri Bartek, Peter Roepstorff, 2003, Molecular & Cellular Proteomics.

Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group.

J. Verweij, R. Sylvester, A. Santoro, 1993, Cancer chemotherapy and pharmacology.

An overview of the EORTC Breast Cancer Cooperative Group's activities.

R. Paridaens, R. Sylvester, H. Mouridsen, 1983, European journal of cancer & clinical oncology.

Letrozole in advanced breast cancer: the PO25 trial

H. Mouridsen, 2007, Breast Cancer Research and Treatment.

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

J. Verweij, A. Santoro, H. Mouridsen, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Detection of metabolic denaturation of serum albumin by gel electrophoresis.

H. Mouridsen, K. Wallevik, 1973, Scandinavian journal of clinical and laboratory investigation.

Endocrine treatment with anti-estrogen, anti-androgen or progestagen of advanced malignant melanoma: three consecutive phase II trials.

H. Mouridsen, C. Rose, L. Pedersen, 1985, European journal of cancer & clinical oncology.

Gastric and pancreatic function and the absorption of iron, vitamin B12, and calcium after proximal gastric resection for cancer in the upper part of the stomach.

H. Mouridsen, H. Worning, K. Fischermann, 1969, Scandinavian journal of gastroenterology.

alpha-fetoprotein levels in maternal serum during pregnancy and maternal breast cancer incidence.

M Lambe, B. No̸rgaard-Pedersen, H. Mouridsen, 2000, Journal of the National Cancer Institute.

Clinical Infrastructures to Support Proteomic Studies of Tissue and Fluids in Breast Cancer*

N. Brünner, H. Mouridsen, 2004, Molecular & Cellular Proteomics.

Fluids in Breast Cancer.

N. Brünner, H. Mouridsen, 2004 .

Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study.

N. Brünner, E. Balslev, B. Rasmussen, 2009, European journal of cancer.

Tumor Tissue Concentrations of the Proteinase Inhibitors Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and Plasminogen Activator Inhibitor Type 1 (PAI-1) Are Complementary in Determining Prognosis in Primary Breast Cancer *

N. Brünner, J. Foekens, I. Christensen, 2003, Molecular & Cellular Proteomics.

N-(phosphonacetyl)-L-aspartate (PALA) in advanced soft tissue sarcoma: a phase II trial of the EORTC soft tissue sarcoma group.

H. Mouridsen, A. V. van Oosterom, V. Bramwell, 1982, European journal of cancer & clinical oncology.

N-(phosphonacetyl)-L-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group.

R. Paridaens, R. Sylvester, H. Mouridsen, 1982, European journal of cancer & clinical oncology.

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.

C. Boni, H. Mouridsen, A. Monnier, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The retention of different plasma proteins in wound tissue.

H. Mouridsen, 1969, Scandinavian journal of clinical and laboratory investigation.

Comparative pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular routes

H. Mouridsen, J. Loeber, M. Salimtschik, 2004, Cancer Chemotherapy and Pharmacology.

Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients.

O. S. Nielsen, M. van Glabbeke, J. Verweij, 2002, European journal of cancer.

High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group.

J. Verweij, R. Sylvester, H. Mouridsen, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.

M. van Glabbeke, D. Crowther, J. Verweij, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial.

P. Sørensen, H. Hansen, H. Mouridsen, 1994, European journal of cancer.

Towards discovery‐driven translational research in breast cancer

P. Guldberg, H. Mouridsen, I. Gromova, 2004, The FEBS journal.

Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.

N. Robert, H. Mouridsen, 2005, MedGenMed : Medscape general medicine.

Marginal surgery and postoperative radiotherapy in soft tissue sarcomas. The Scandinavian Sarcoma Group experience.

C. Blomqvist, H. Mouridsen, A. Rydholm, 1993, European journal of cancer.

Soft tissue sarcomas in adults. Surgical, radiologic and cytotoxic treatment.

H. Mouridsen, H. Johansen, C. Arnoldi, 1984, Acta radiologica. Oncology.

A pharmacokinetic study of prednimustine as compared with prednisolone plus chlorambucil in cancer patients

L. Bastholt, H. Mouridsen, P. Pfeiffer, 2004, Cancer Chemotherapy and Pharmacology.

Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial

B. Rasmussen, H. Mouridsen, J. Overgaard, 1999, The Lancet.

High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.

N. Brünner, I. Christensen, H. Mouridsen, 1993, Cancer research.

Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study.

M. van Glabbeke, J. Verweij, H. Mouridsen, 1994, European journal of cancer.

Flow cytometric DNA ploidy defines patients with poor prognosis in node‐negative breast cancer

I. Christensen, P. Briand, I. Balslev, 2007, International journal of cancer.

Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol

H. Mouridsen, M. Overgaard, M. Nielsen, 2008, Acta oncologica.

Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancer.

M. Ro̸rth, S. Larsen, H. Mouridsen, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The effect of chloramphenicol and sulphaphenazole on the biotransformation of cyclophosphamide in man.

H. Mouridsen, L. Skovsted, O. Faber, 1975, British journal of clinical pharmacology.

Reproductive risk factors for breast cancer by receptor status, histology, laterality and location

H. Mouridsen, M. Melbye, J. Wohlfahrt, 1999, International journal of cancer.

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women

Jack Cuzick, R. Collins, J. Crowley, 1988 .

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

A. Giobbie-Hurder, J. Forbes, R. Gelber, 2009, The New England journal of medicine.

Phase II trial of methylene dimethane sulphonate (MDMS) in advanced soft tissue sarcomas of the adult. A study of the EORTC Soft Tissue and Bone Sarcoma Group.

J. Verweij, R. Sylvester, H. Mouridsen, 1989, European journal of cancer & clinical oncology.

The application of whole-body counting to studies of the turnover of 131I-labelled plasma proteins.

H. Mouridsen, J. Bojsen, M. Fabier, 1969, Scandinavian Journal of Clinical and Laboratory Investigation.

Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group.

H. Mouridsen, C. Rose, K. Andersen, 1992, Journal of the National Cancer Institute. Monographs.

Prognostic factors in osteosarcomas. A regression analysis

H. Mouridsen, S. Kaae, H. Johansen, 1988, Cancer.

Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark.

B. Rasmussen, H. Mouridsen, M. Ewertz, 2011, Journal of the National Cancer Institute.

Medullary carcinoma of the breast, proposal for a new simplified histopathological definition. Based on prognostic observations and observations on inter- and intraobserver variability of 11 histopathological characteristics in 131 breast carcinomas with medullary features.

K. Zedeler, H. Mouridsen, T. Schiødt, 1991, British Journal of Cancer.

Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status

E. Balslev, K. Nielsen, H. Mouridsen, 2012, Molecular oncology.

Tissue inhibitor of metalloproteinases-1 in breast cancer.

N. Brünner, I. Christensen, H. Mouridsen, 2005, Endocrine-related cancer.

The biotransformation of cyclophosphamide in man: influence of prednisone.

H. Mouridsen, L. Skovsted, O. Faber, 2009, Acta pharmacologica et toxicologica.

Molecular cytogenetic analysis of a nontumorigenic human breast epithelial cell line that eventually turns tumorigenic: Validation of an analytical approach combining karyotyping, comparative genomic hybridization, chromosome painting, and single‐locus fluorescence in situ hybridization

L. Bolund, P. Briand, M. Madsen, 1997, Genes, chromosomes & cancer.

Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer

E. Balslev, K. Nielsen, B. Rasmussen, 2011, Breast Cancer Research and Treatment.

The transcapillary passage of different proteins in the operative wound

H. Mouridsen, K. Wallewick, 1969 .

Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.

N. Brünner, I. Christensen, P. Briand, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

KAPOSI'S SARCOMA IN HOMOSEXUAL MEN: IS IT A NEW DISEASE

H. Mouridsen, K. Thomsen, K. Jensen, 1982, The Lancet.

BENEFICIAL EFFECT OF ADJUVANT TAMOXIFEN THERAPY IN PRIMARY BREAST CANCER PATIENTS WITH HIGH OESTROGEN RECEPTOR VALUES

B. Rasmussen, H. Mouridsen, C. Rose, 1985, The Lancet.

Phase II study with Docetaxel (Taxotere®) in advanced soft tissue sarcomas of the adult

J. Verweij, M. Glabbeke, H. Mouridsen, 1994 .

Anti-estrogen treatment of postmenopausal breast cancer patients with high risk of recurrence: 72 months of life-table analysis and steroid hormone receptor status

H. Mouridsen, C. Rose, K. Andersen, 1985, World Journal of Surgery.

Adjuvant treatment of postmenopausal patients with high risk primary breast cancer. Results from the Danish adjuvant trials DBCG 77 C and DBCG 82 C.

B. Rasmussen, H. Mouridsen, P. Dombernowsky, 1988, Acta oncologica.

Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer

N. Brünner, M. Fernö, J. Foekens, 2010, Breast Cancer Research and Treatment.

TIMP-1 as a tumor marker in breast cancer – An update

N. Brünner, H. Mouridsen, A. Schrohl, 2008, Acta oncologica.

The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival.

N. Brünner, I. Christensen, P. Briand, 2000, Cancer research.

Danish Breast Cancer Cooperative Group (DBCG). A description of the register of the nation-wide programme for primary breast cancer.

H. Mouridsen, K. Andersen, H. Mouridsen, 1988, Acta oncologica.

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.

C. Boni, H. Mouridsen, F. Jänicke, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Symptoms of endocrine treatment and outcome: A retrospective analysis of the monotherapy arms of the BIG 1-98 trial.

A. Giobbie-Hurder, J. Forbes, R. Paridaens, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG).

C. Axelsson, K. Zedeler, H. Mouridsen, 1992, European journal of cancer.

Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized EORTC study of CMF vs CMF + tamoxifen.

R. Sylvester, H. Mouridsen, C. Rose, 1985, Journal of steroid biochemistry.

Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized study of CMF vs CMF plus tamoxifen.

R. Sylvester, H. Mouridsen, C. Rose, 1985, European journal of cancer & clinical oncology.

Histopathological grade and response to chemotherapy in advanced soft tissue sarcomas.

H. Mouridsen, T. Schiødt, S. Daugaard, 1993, European journal of cancer.

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

C. Sotiriou, C. Desmedt, D. Larsimont, 2011, The Lancet. Oncology.

HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients.

Nils Brünner, N. Brünner, E. Balslev, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lack of TIMP-1 tumor cell immunoreactivity predicts effect of adjuvant anthracycline based chemotherapy in patients (n=647) with primary breast cancer.

N. Brünner, E. Balslev, H. Mouridsen, 2009 .

Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group

O. S. Nielsen, M. van Glabbeke, J. Verweij, 2000, Sarcoma.

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group.

O. S. Nielsen, M. van Glabbeke, D. Crowther, 1998, British Journal of Cancer.

Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group.

J. Mulder, L. Bastholt, A. Santoro, 1987, European journal of cancer & clinical oncology.

Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BIG 1-98: A randomized double-blind phase III study comparing letrozole and tamoxifen given in sequence vs. alone as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer.

J. Forbes, R. Gelber, R. Paridaens, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic effect of estrogen receptor status across age in primary breast cancer

B. Rasmussen, H. Mouridsen, N. Kroman, 2007, International journal of cancer.

Effect of breast‐conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma

H. Mouridsen, M. Melbye, N. Kroman, 2004 .

Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.

J. Forbes, R. Gelber, B. Gusterson, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D

M. Bonetti, R. Gelber, D. Zahrieh, 2010, Breast Cancer Research and Treatment.

The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D

H. Mouridsen, S. Møller, B. Ejlertsen, 2008, Acta oncologica.

Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration

H. Mouridsen, J. Overgaard, N. Kroman, 2018, Acta oncologica.

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Review of the clinical trials activity of the Soft Tissue and Bone Sarcoma Group of the European Organization for Research and Treatment of Cancer.

J. Mulder, A. Santoro, H. Mouridsen, 1988, Seminars in surgical oncology.

Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer co-operative Group DBCG 82B Trial.

H. Mouridsen, M. Andersson, P. Dombernowsky, 1999, European journal of cancer.

Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer

M. Beckmann, P. Lønning, K. Blackwell, 2010, Expert review of anticancer therapy.

Editorial

H. Mouridsen, 2010 .

The differences in outcome between ATAC and BIG 1-98 suggest efficacy differences between these two nonsteroidal AIs.

H. Mouridsen, 2010, Cancer investigation.

Medullary carcinoma of the breast, prognostic importance of characteristic histopathological features evaluated in a multivariate Cox analysis.

K. Zedeler, H. Mouridsen, T. Schiødt, 1994, European journal of cancer.

E.O.R.T.C. phase II study of cisplatin in cyvadic-resistant soft tissue sarcoma.

R. Sylvester, H. Mouridsen, A. V. van Oosterom, 1979, European journal of cancer.

VP-16 in advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and bone sarcoma group.

A. Santoro, H. Mouridsen, V. Bramwell, 1987, European journal of cancer & clinical oncology.

Mitomycin C (MCC) in advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.

R. Sylvester, A. Santoro, H. Mouridsen, 1985, European journal of cancer & clinical oncology.

Endocrine Treatment of Malignant Disease

H. Mouridsen, 1993 .

Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.

O. S. Nielsen, L. Bastholt, H. Mouridsen, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carminomycin versus doxorubicin in advanced breast cancer, a randomized phase II study of the E.O.R.T.C. Breast Cancer Cooperative Group.

R. Paridaens, R. Sylvester, H. Mouridsen, 1986, European journal of cancer & clinical oncology.

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.

István Láng, A. Giobbie-Hurder, J. Forbes, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG

H. Mouridsen, M. Andersson, P. Dombernowsky, 1999, European journal of cancer.

Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high‐risk, premenopausal breast cancer

H. Mouridsen, M. Andersson, M. Jensen, 2010, Cancer.

The occurrence of fractures after adjuvant treatment of breast cancer: a DBCG register study

H. Mouridsen, M. Jensen, B. Ejlertsen, 2018, Acta oncologica.

Danish Breast Cancer Cooperative Group

H. Mouridsen, M. Jensen, B. Ejlertsen, 2016, Clinical epidemiology.

[Danish Breast Cancer Cooperative Group].

H. Mouridsen, S. Møller, P. Christiansen, 2012, Ugeskrift for laeger.

Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study.

H. Mouridsen, B. Ejlertsen, I. Transbøl, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient's and doctor's delay in primary breast cancer. Prognostic implications.

H. Sommer, K. Zedeler, H. Mouridsen, 1994, Acta oncologica.

Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).

H. Mouridsen, B. Ejlertsen, M. Kjaer, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant therapy of premenopausal and menopausal high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group Trials 77-B and 82-B.

H. Mouridsen, P. Dombernowsky, C. Rose, 1988, Acta oncologica.

Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer.

H. Mouridsen, P. Dombernowsky, C. Rose, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months.

H. Mouridsen, C. Rose, M. Overgaard, 1993, European journal of cancer.

Metastatic pattern in recurrent breast cancer: Special reference to intrathoracic recurrences

H. Mouridsen, I. Vejborg, L. Olsen, 1988, Cancer.

An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer

B. Rasmussen, H. Mouridsen, A. Lykkesfeldt, 2009, Acta oncologica.

Letrozole in advanced breast cancer: the PO25 trial

H. Mouridsen, 2007, Breast Cancer Research and Treatment.

A Danish randomized trial comparing breast-preserving therapy with mastectomy in mammary carcinoma. Preliminary results.

G. Knudsen, H. Mouridsen, P. Dombernowsky, 1988, Acta oncologica.

Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer.

B. Rasmussen, H. Mouridsen, M. Overgaard, 2009, Journal of the National Cancer Institute.

A modified Nottingham prognostic index for breast cancer patients diagnosed in Denmark 1978-1994.

H. Mouridsen, K. Rostgaard, E. Lynge, 2001, Acta oncologica.

Vimentin expression in 98 breast cancers with medullary features and its prognostic significance

K. Zedeler, H. Mouridsen, T. Schiødt, 2005, Virchows Archiv A.

The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007–2016

A. Laenkholm, H. Mouridsen, N. Kroman, 2018, Acta oncologica.

Impact of Axillary Dissection on Staging and Regional Control in Breast Tumors = 10 mm: The DBCG experience

H. Mouridsen, C. Axelsson, M. Jensen, 2000 .

Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study

Elsebeth Lynge, H. Mouridsen, I. Vejborg, 2005, BMJ : British Medical Journal.

Clinical Impact of Introduction of Mammography Screening in a Non-Screening Country

H. Mouridsen, I. Vejborg, F. Rank, 2002, Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society.

Prognostic Factors in Node-Negative Breast Cancer Patients

I. Balslev, K. Zedeler, B. Rasmussen, 1990 .

Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays

B. Rasmussen, H. Mouridsen, A. Lykkesfeldt, 2006, Journal of Clinical Pathology.

Clinical and radiologic characteristics of bone metastases in breast cancer

H. Mouridsen, I. Vejborg, S. Daugaard, 1987, Cancer.

DBCG trial 89B comparing adjuvant CMF and ovarian ablation: Similar outcome for eligible but non-enrolled and randomized breast cancer patients

H. Mouridsen, M. Ewertz, M. Jensen, 2008, Acta oncologica.

Influence of tumor location on breast cancer prognosis

Mads Melbye, H. Mouridsen, M. Melbye, 2003, International journal of cancer.

Danish Breast Cancer Cooperative Group – DBCG: History, organization, and status of scientific achievements at 30-year anniversary

H. Mouridsen, P. Christiansen, Mogens Blichert-Toft, 2008, Acta oncologica.

Do changes in lymph node status distribution explain trends in survival of breast cancer patients in Denmark?

H. Mouridsen, K. Rostgaard, E. Lynge, 2006, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

A model for determining the effect of mammography service screening

H. Mouridsen, I. Vejborg, M. Jensen, 2005, Acta oncologica.

Ifosfamide plus Adriamycin in Advanced Soft Tissue Sarcomas

R. Sylvester, A. Santoro, H. Mouridsen, 1987 .

Improvements in breast cancer survival between 1995 and 2012 in Denmark: The importance of earlier diagnosis and adjuvant treatment

H. Mouridsen, M. Jensen, B. Ejlertsen, 2016, Acta oncologica.

Endocrine Therapy In Primary and Advanced Breast Cancer

H. Mouridsen, 1986 .

Site-specific effect of chemotherapy in patients with breast cancer.

H. Mouridsen, C. Kamby, P. M. Vestlev, 1992, Acta oncologica.

Antiestrogen treatment of postmenopausal women with primary high risk breast cancer

H. Mouridsen, C. Rose, K. Andersen, 1983, Breast Cancer Research and Treatment.

Therapeutic effect of tamoxifen related to estrogen receptor level.

H. Mouridsen, C. Rose, T. Palshof, 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

PredictingRecurrencein Patientswith BreastCancer from Cumulative LaboratoryResults:A New Techniquefor the Applicationof Time Series Analysis

H. Mouridsen, P. Winkel, M. W. Bentzon, 1982 .

Anxiety and depression in breast cancer patients at low risk of recurrence compared with the general population: a valid comparison?

P. Fayers, N. Aaronson, J. Bjorner, 1999, Journal of clinical epidemiology.

Depression as a prognostic factor for breast cancer mortality.

N. Keiding, P. Mortensen, H. Mouridsen, 2003, Psychosomatics.

Depression as prognostic factor in breast cancer

E. W. Olsen, N. Keiding, P. Mortensen, 1998 .

J. Bergh, H. Mouridsen, N. Bengtsson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapeutic effect of tamoxifen versus combined tamoxifen and diethylstilboestrol in advanced breast cancer in postmenopausal women.

M. Ro̸rth, H. Mouridsen, P. Dombernowsky, 1980, European journal of cancer.

Improvement of prognosis in breast cancer in Denmark 1977–2006, based on the nationwide reporting to the DBCG Registry

H. Mouridsen, M. Jensen, S. Møller, 2008, Acta oncologica.

The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients

T. Nielsen, S. Ferree, E. Balslev, 2020, npj Breast Cancer.

The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients

T. Nielsen, S. Ferree, E. Balslev, 2020, npj Breast Cancer.

Risk of late-stage breast cancer after a childbirth.

P. Andersen, H. Mouridsen, M. Melbye, 2001, American journal of epidemiology.

The place of chemotherapy in the management of soft tissue sarcoma: experiences of the EORTC Soft Tissue and Bone Sarcoma Group.

J. Verweij, A. Santoro, H. Mouridsen, 1989, Clinical oncology (Royal College of Radiologists (Great Britain)).

Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial.

E. Balslev, H. Mouridsen, M. Andersson, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Timing of surgery in relation to menstrual cycle does not predict the prognosis in primary breast cancer. Danish Breast Cancer Cooperative Group.

H. Mouridsen, K. Andersen, N. Kroman, 1994, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.

B. Rasmussen, H. Mouridsen, M. Andersson, 2013, European journal of cancer.

Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer

H. Mouridsen, M. Jensen, B. Ejlertsen, 2014, Acta oncologica.

674 Topoisomerase II alpha (TOP2A) alterations as a predictive marker for epirubicin sensitivity in 805 high-risk breast cancer patients. A randomised DBCG trial (DBCG89D)

E. Balslev, K. Nielsen, B. Rasmussen, 2003 .

Treatment costs of adjuvant cytotoxic therapy in premenopausal breast cancer patients.

H. Mouridsen, J. Søgaard, J. Jorgensen, 1988, Acta oncologica.

The pharmacokinetics of cyclophosphamide in man following treatment with methotrexate.

H. Mouridsen, E. Jacobsen, O. Faber, 2009, Acta pharmacologica et toxicologica.

Axillary staging during surgery for breast cancer

H. Mouridsen, C. Axelsson, M. Düring, 2007, The British journal of surgery.

Adjuvant endocrine therapy of breast cancer--a controlled clinical trial of oestrogen and anti-oestrogen: preliminary results of the Copenhagen breast cancer trials.

H. Mouridsen, T. Palshof, J. Daehnfeldt, 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

The Turnover in Humans of Polymerized Human Serum Albumin and of Fractions of Human Serum Albumin with Different N–F Transformation Patterns

H. Mouridsen, K. Wallevik, 1969 .

Turnover of human serum albumin before and after operations.

H. Mouridsen, 1967, Clinical science.

Long-term results of breast conserving surgery vs . mastectomy for early stage invasive breast cancer : 20-year follow-up of the Danish randomized DBCG-82 TM protocol

ller, H. Mouridsen, M. Overgaard, 2008 .

Do clinical databases render population-based cancer registers obsolete? The example of breast cancer in Denmark

H. Mouridsen, K. Rostgaard, E. Lynge, 2000, Cancer Causes & Control.

Second-line chemotherapy with tauromustine in metastatic breast cancer in postmenopausal women: a phase II study.

I. Balslev, H. Mouridsen, P. Ernst, 1987, Cancer treatment reports.

Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group.

J. Verweij, A. Santoro, H. Mouridsen, 1990, European journal of cancer.

Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial.

R. Gelber, G. Viale, M. Regan, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[Adjuvant endocrine treatment of postmenopausal patients with breast cancer with high risk of recurrence. 5. Results from the DBCG (Danish Breast Cancer Cooperative Group) 77C randomized trial].

H. Mouridsen, P. Dombernowsky, C. Rose, 1991, Ugeskrift for læger.

Endometrial carcinoma and tamoxifen: clearing up a controversy.

H. Storm, H. Mouridsen, M. Andersson, 1996, Clinical Cancer Research.

A randomized phase III trial of adjuvant endocrine therapy with tamoxifen for one year (TAM1) vs tamoxifen for two years (TAM2) in postmenopausal high risk patients with estrogen receptor positive or estrogen receptor unknown breast cancer. A DBCG study

F. Hirsch, H. Mouridsen, M. Andersson, 1998 .

[Adjuvant chemotherapy in premenopausal and menopausal high-risk patients with breast cancer. 4. Results of the DBCG (Danish Breast Cancer Cooperative Group) 77B study].

B. Rasmussen, H. Mouridsen, P. Dombernowsky, 1991, Ugeskrift for laeger.

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Bingshu E. Chen, R. Gray, P. Lønning, 2023, The Lancet.

Reproductive history and stage of breast cancer.

H. Adami, P. Andersen, H. Mouridsen, 1999, American journal of epidemiology.

Treatment of advanced breast cancer with progestins.

H. Mouridsen, C. Rose, M. Salimtschik, 1981, Acta obstetricia et gynecologica Scandinavica. Supplement.

Extended radical mastectomy versus simple mastectomy followed by radiotherapy in primary breast cancer. A fifty-year follow-up to the Copenhagen Breast Cancer randomised study

H. Mouridsen, S. Kaae, H. Johansen, 2008, Acta oncologica.

Inappropriate ATAC on tamoxifen.

B. Thürlimann, H. Mouridsen, A. Coates, 2008, The Lancet. Oncology.

[Treatment of primary breast cancer. Consequences of mammographic screening in the municipality of Copenhagen].

F. Hirsch, H. Mouridsen, M. Jensen, 1996, Ugeskrift for laeger.

Classical prognostic factors in node-negative breast cancer: the DBCG experience.

B. Rasmussen, H. Mouridsen, P. Dombernowsky, 1992, Journal of the National Cancer Institute. Monographs.

Correspondence re: V. C. Jordan and V. J. Assikis, Endometrial Carcinoma and Tamoxifen: Clearing Up a Controversy. Ciin. Cancer Res., 1: 467-472, 1995.

H. Storm, H. Mouridsen, M. Andersson, 1996 .

[Should all younger patients with breast cancer be offered adjuvant cytotoxic chemotherapy?].

P. Andersen, H. Mouridsen, M. Melbye, 2000, Ugeskrift for laeger.

Tamoxifen treatment of advanced endometrial carcinoma. A phase II study.

H. Mouridsen, M. Salimtschik, I. Hald, 1983, European Journal of Gynaecological Oncology.

TOP2A aberrations as predictive and prognostic marker in high-risk breast cancer patients. A randomized DBCG Trial (DBCG89D).

E. Balslev, K. Nielsen, B. Rasmussen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activity of adriamycin in metastatic breast cancer resistant to a combination regimen with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prdnisone.

H. Mouridsen, K. Roesdahl, S. Joergensen, 1978, Cancer treatment reports.

Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer.

J. Bergh, P. Malmström, L. Hakamies‐Blomqvist, 2003, European journal of cancer.

Currently active protocols in the EORTC Breast Cancer Cooperative Group.

R. Paridaens, R. Sylvester, H. Mouridsen, 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

The presence of tumor cells in bone marrow at the time of first recurrence of breast cancer

H. Mouridsen, I. Vejborg, S. Daugaard, 1987, Cancer.

Bmc Cancer

B. Rasmussen, H. Mouridsen, H. Sasano, 2022 .

Discussion at the Satellite symposium: Ifosfamide in gynecological tumors

H. Mouridsen, E. Wiltshaw, A. Pfleiderer, 2004, Cancer Chemotherapy and Pharmacology.

Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group.

J. Bergh, P. Malmström, L. Hakamies‐Blomqvist, 2000, European journal of cancer.

The extravascular retention of albumin in wound tissue and its contribution to the postoperative hypoalbuminaemia in rabbits.

H. Mouridsen, 1969, Clinical science.

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

A. Giobbie-Hurder, J. Forbes, R. Gelber, 2009, The New England journal of medicine.